GLP-1 Collective

Policy Tracker · Patient Lens · July 25, 2026

Another lawsuit says Novo Nordisk itself set Ozempic's list price too high

The claim rests on a single question: whether a drugmaker can be sued for pricing its own product.

Nothing new was filed in the last day. These are the 3 most recent developments affecting GLP-1 access that this tracker has not covered yet, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Polkabla sues Novo Nordisk over GLP-1 practices](/lawsuits/cl-73654861)**.

**[Patient sues Novo Nordisk over Ozempic and Wegovy pricing barriers](/lawsuits/cl-73652440)**.

**[Lawsuit challenges Novo Nordisk's GLP-1 pricing and marketing](/lawsuits/cl-73648427)**.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.